IMVT/ 01/06/2026 · 9:25 AM Wolfe Research Upgrades Immunovant to Outperform with $50 Target Wolfe Research upgrades Immunovant stock, citing higher valuation support, declining short interest, and positive catalysts ahead in 2026.
